Article

Circulating tumor DNA in neoadjuvant treated breast cancer reflects response and survival

2020-02-05

Abstract excerpt

Pathologic complete response (pCR) to neoadjuvant chemotherapy (NAC) is strongly associated with favorable outcome. We examined the utility of serial circulating tumor DNA (ctDNA) testing for predicting pCR and risk of metastatic recurrence in 84 high-risk early breast cancer patients treated in the neoadjuvant I-SPY 2 TRIAL. Cell-free DNA (cfDNA) was isolated from 291 plasma samples collected at pretreatment (T0)...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: c79d4e5d-8c7b-58c7-837c-e47d5d4a5a66
DOI: 10.1101/2020.02.03.20019760

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Circulating tumor DNA in neoadjuvant treated breast cancer reflects response and survivalDOI 10.1101/2020.02.03.20019760Read

Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival.Semantic proximity Read

Circulating tumor DNA refines risk stratification of neoadjuvant therapy-resistant breast tumors.Semantic proximity Read

Prognostic and monitoring value of circulating tumor DNA at multiple clinical time points in breast cancer.Semantic proximity Read

Circulating tumor DNA as a predictive marker of recurrence for patients with stage II-III breast cancer treated with neoadjuvant therapySemantic proximity Read

Serial Circulating Tumor DNA Identification Associated with the Efficacy and Prognosis of Neoadjuvant Chemotherapy in Breast CancerSemantic proximity Read

Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030Semantic proximity Read

Next-generation sequencing of circulating tumor DNA to predict recurrence in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapySemantic proximity Read

Serial circulating tumor DNA identification associated with the efficacy and prognosis of neoadjuvant chemotherapy in breast cancer.Semantic proximity Read

Blood-based genomics of triple-negative breast cancer progression in patients treated with neoadjuvant chemotherapySemantic proximity Read

Dynamic ctDNA tracking stratifies individual relapse risk for early triple negative breast cancer patients receiving neoadjuvant chemotherapySemantic proximity Read

Prognostic value of circulating tumor DNA mutation panels to predict early recurrence and survival outcomes in early-stage breast cancer: a systematic review and meta-analysis.Semantic proximity Read

Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.Semantic proximity Read